The abstract is read at the publisher; the summary is JClub's.
Perineural invasion in SNF1 HR+/HER2- breast cancer is linked to diminished endocrine therapy efficacy, suggesting perineural blockade may improve outcomes.
- Why it matters: Subtyping-directed precision treatment helps locally advanced HR+/HER2- disease, but response rates remain suboptimal, motivating refinement of subtype-specific strategies.
- What they did: Using multimodal data from the FASCINATE-N trial (n = 230), the study analyzed exceptional responders with transcriptomic, genomic, digital pathology, and clinical measures to probe subtype vulnerabilities.
- The result: Across SNF1–SNF4, multimodal signals (including tumor-stromal-immune interface architecture, DNA repair/cell cycle alterations, and lymphatic vessel infiltration) refine how therapies like apatinib, PARP and CDK4/6 inhibitors, and immunotherapy may be matched to HR+/HER2- subtypes.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.